L Robson
11 Papers
175 Citations
L Robson is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & PARP inhibitor. The author has an hindex of 8, co-authored 11 publications.
Chat about Author
Papers
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer,Chris Jones,Mark R. Middleton,Richard H. Wilson,Jeff Evans,Anna L. Olsen,Nicola J. Curtin,Alan V. Boddy,Peter J. McHugh,David R. Newell,Adrian L. Harris,Patrick Johnson,Heidi Steinfeldt,R. Dewji,Diane Wang,L Robson,Hilary Calvert +16 more
TL;DR: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents is shown.
402
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT).
Donald Bissett,Jim Cassidy,J.S. de Bono,F Muirhead,M Main,L Robson,D Fraier,M L Magnè,C Pellizzoni,M G Porro,R Spinelli,W Speed,Chris Twelves +12 more
TL;DR: The objectives of this study were to determine the maximum tolerated dose, dose-limiting toxicities, and the plasma and urine pharmacokinetics of MAG-CPT, and to document responses to this treatment.
127
Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
Emma Dean,Duncan I. Jodrell,Kate Connolly,Sarah Danson,Jacques Jolivet,J Durkin,Stephen Morris,Debra Jowle,Timothy H Ward,Jeffrey Cummings,Gemma L. Dickinson,Leon Aarons,Eric C. LaCasse,L Robson,Caroline Dive,Malcolm R Ranson +15 more
TL;DR: In this first-in-man study, AEG35156 was well tolerated, with predictable toxicities, pharmacokinetic properties, and clinical evidence of antitumor activity in patients with refractory lymphoma, melanoma, and breast cancer.
95
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors
Ruth Plummer,Mark R. Middleton,Richard K. Wilson,Chris Jones,J. Evans,L Robson,Heidi Steinfeldt,R Kaufman,S. D. Reich,Alan Hilary Calvert +9 more
TL;DR: Overall objective based on xenograft data was to achieve > 40% PARP inhibition in tumor.
45
•Journal Article
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
David Porter,Alan V. Boddy,Huw D. Thomas,Michael J. Lind,David R. Newell,Alan Hilary Calvert,L Robson,M Brampton,D Abrahamsen,B. Winograd +9 more
TL;DR: Therapeutic drug monitoring was shown to reduce the interpatient variation in the plasma etoposide concentration by half and shows promise for individualizing treatment with combination chemotherapy.
14